AstraZeneca and Rigel in a US$1.2 B Deal for Rheumatoid Arthritis
By Taskin Ahmed
Pharma Deals Review: Vol 2010 Issue 2 (Table of Contents)
Published: 22 Feb-2010
DOI: 10.3833/pdr.v2010.i2.1315 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
AstraZeneca has entered the rheumatoid arthritis market by agreeing to develop and commercialise Rigel’s rheumatoid arthritis drug, R788, that is about to enter Phase III clinical trials...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS